Damona Pharmaceuticals Analysis: $6M Raised
What is Damona Pharmaceuticals?
Microcircuit precision medicines for cognitive disorders
Location
Toronto, Canada
Employees
1-10
Founded
2019
Product Features & Capabilities
- DPX-101, a positive allosteric modulator targeting α5-GABA-A receptor
Use Cases
Treat cognitive deficits in Alzheimer's disease; Address cognitive impairments across various brain disorders; Restore connections between brain cells; Improve life quality for patients with cognitive deficits; Support clinical trials for neurological therapies
Other Considerations
Published preclinical proof of concept data for DPX-101; IND application clearance for Phase 1 trial of DPX-101; Focus on cognitive deficits in Alzheimer's and other brain disorders
See something that needs updating? Suggest edits to this profile.